Previous 10 | Next 10 |
home / stock / ivevf / ivevf news
Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of p...
Proposed changes are expected to be beneficial to the lanifibranor clinical program by reducing the number of biopsies and the trial duration, eventually offering all patients in the trial access to treatment and potentially expanding the addressable patient population to patients with NASH and c...
Summary Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharm, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from France’s Inventiva in a $307 million deal. Immuno Cure, a Hong Kong biotech focused on DNA vaccines and immunotherapies, acq...
Inventiva S.A. (IVA) Q2 2022 Earnings Conference Call September 22, 2022, 8:00 AM ET Company Participants Frédéric Cren - Co-Founder and CEO Pierre Broqua - Co-Founder and CSO Michael Cooreman - Chief Medical Officer Jean Volatier - Chief Financial ...
This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...
Inventiva S.A. (IVA) Q4 2021 Earnings Conference Call March 08, 2022 08:00 AM ET Company Participants Frédéric Cren - Chairman, Chief Executive Officer & Co-Founder Pierre Broqua - Chief Scientific Officer & Co-Founder Michael Cooreman - Chief Medical Officer Jean Volatier -...
Inventiva S.A. (IVA) Q2 2021 Results Conference Call September 21, 2021 08:00 AM ET Company Participants Frédéric Cren - Chairman, CEO and Co-Founder Pierre Broqua - CSO and Co-Founder Michael Cooreman - CMO Jean Volatier - CFO Conference Call Participants Lucy Codrington - Jefferie...
The following slide deck was published by Inventiva S.A. in conjunction with this event. For further details see: Inventiva (IVA) Investor Presentation - Slideshow
Inventiva S.A. (IVEVF) Q4 2020 Earnings Conference Call March 5, 2021 08:00 ET Company Participants Frédéric Cren - Chairman, Chief Executive Officer and Co-Founder Pierre Broqua - Chief Scientific Officer and Co-Founder Michael Cooreman - Chief Medical Officer Jean Volatier - Chief...
The following slide deck was published by Inventiva S.A. in conjunction with this event. For further details see: Inventiva (IVEVF) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Japanese Patent Office approved Inventiva’s patent application relating to the use of lanifibranor for the treatment of cirrhosis. 1 This patent strengthens Inventiva’s intellectual property with respect to lanifibranor in Japan for the indication cirrhosis, including cirrho...
Royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng). Royalty of 3% on future net sales of lanifibranor in the United States of America, the European Union and the United Kingdom over a 14-year term. Cash runway extended...
Recruitment in NATiV3 clinical trial continues in both cohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the exploratory cohort of NATiV3. Analysis of the baseline characteristics of all patients randomized in the main cohort of NATiV3 show a pat...